LOOK TO
GAVRETO is the only once-daily therapy designed to selectively target RET1
LOOK TO
PUSH RET
BACK
GAVRETO is the only once-daily therapy designed to selectively target RET1
*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC and thyroid carcinoma for detailed recommendations, including other preferred treatment options.2,3
†For structurally persistent/recurrent locoregional or distantly metastatic RET fusion-positive differentiated thyroid cancer not amenable to RAI therapy and for metastatic RET fusion-positive anaplastic thyroid carcinoma.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
mNSCLC=metastatic non–small cell lung cancer; RAI=radioactive iodine; RET=rearranged during transfection.
References:
1. GAVRETO® [Package insert], South San Francisco, CA: Rigel Pharmaceuticals, Inc.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 2, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 2, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.